SYSTEMATIC REVIEW article
Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review
- 1Laboratório de Bioinformática e Química Computacional, Departamento de Ciências Biológicas, Universidade Estadual do Sudoeste da Bahia (UESB), Jequié, Brazil
- 2Programa de Pós-graduação em Genética e Biologia Molecular, Universidade Estadual de Santa Cruz, Ilhéus, Brazil
- 3Departamento de Saúde II, Universidade Estadual do Sudoeste da Bahia, Jequié, Brazil
- 4Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology (IIOAB), Purba Medinipur, India
- 5Laboratório de Biologia Molecular e Computacional de Fungos, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil
- 6Departamento de Patologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil
- 7Laboratório de Genética Celular e Molecular, Departamento de Biologia Geral, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
The SARS-CoV-2 outbreak originally appeared in China in December 2019 and became a global pandemic in March 2020. This infectious disease has directly affected public health and the world economy. Several palliative therapeutic treatments and prophylaxis strategies have been used to control the progress of this viral infection, including pre-(PrEP) and post-exposure prophylaxis. On the other hand, research groups around the world are still studying novel drug prophylaxis and treatment using repurposing approaches, as well as vaccination options, which are in different pre-clinical and clinical testing phases. This systematic review evaluated 1,228 articles from the PubMed and Scopus indexing databases, following the Kitchenham bibliographic searching protocol, with the aim to list drug candidates, potentially approved to be used as new options for SARS-CoV-2 prophylaxis clinical trials and medical protocols. In searching protocol, we used the following keywords: “Covid-19 or SARS-CoV-2” or “Coronavirus or 2019 nCoV,” “prophylaxis,” “prophylactic,” “pre-exposure,” “COVID-19 or SARS-CoV-2 Chemoprophylaxis,” “repurposed,” “strategies,” “clinical,” “trials,” “anti-SARS-CoV-2,” “anti-covid-19,” “Antiviral,” “Therapy prevention in vitro,” in cells “and” human testing. After all protocol steps, we selected 60 articles that included: 15 studies with clinical data, 22 studies that used in vitro experiments, seven studies using animal models, and 18 studies performed with in silico experiments. Additionally, we included more 22 compounds between FDA approved drugs and drug-like like molecules, which were tested in large-scale screenings, as well as those repurposed approved drugs with new mechanism of actions. The drugs selected in this review can assist clinical studies and medical guidelines on the rational repurposing of known antiviral drugs for COVID-19 prophylaxis.
The SARS-CoV-2 outbreak originally appeared in China in December 2019 and became a global pandemic in March 2020 (Xie et al., 2020). This infectious disease made a direct impact on global public health, and is still impairing the world economy (World Health Organization, 2020). In order to minimize and prevent the advance of COVID-19 and its effects, the world scientific community has been doing an unprecedented race in many research fields, resulting in many discoveries in viral biology, disease physiopathology, and new more effective and cost-beneficial therapeutic options to be used for the treatment of people affected by the new virus (Vellingiri et al., 2020).
Prophylactic drugs can be used both to block the pathogen’s infectious cycle and/or to boost host immunity (Glushkov et al., 1999). There are two main categories of prophylaxis (I) pre-exposure prophylaxis (PrEP), which considers that treated individuals that had no contact with the pathogen (II) post-exposure prophylaxis (PEP), which includes individuals that may have been infected (e.g. contact with patients) but have not exhibited the disease symptoms (Zhang et al., 2020). These two models of prophylactic studies have been extensively used in endemic viral pathologies with high transmissivity, such as HIV (Krakower et al., 2015). Additionally, both methods exhibited success for other viral diseases with great global health impact (Mayer et al., 2015). PrEP and PEP have proven to be extremely effective strategies in viral transmission control for patients inside certain risk groups, such as those with comorbidities, and health professionals directly exposed to the risk of acquiring and transmitting Covid-19 (Rockstroh et al., 2020).
Prophylactic antiviral treatment is an important approach for rational drug administration since it can be used to block the disease evolution and to spread and reduce the risks of side and adverse effects, as well as toxicity in patients (Beigel et al., 2019; Cheng, 2019). Because of SARS-CoV-2 high degree of transmissivity, novel therapeutic ways that can reach the affected patients faster became necessary (Kang et al., 2020). Among many therapeutic strategies, drug repurposing has been reaching significant results against some pathogens (Cheng et al., 2016; Cheng, 2019). Drugs approved for human diseases can be repurposed for new targets in order to speed up the process of implementing these compounds in clinical protocols for the treatment and prophylaxis in the acute phase of viral diseases. Moreover, this approach is instrumental in preventing the viral transmission to healthy individuals (Zhou et al., 2020).
Currently, several preclinical studies, such as in silico, in vitro and in vivo trials have been guiding clinical decisions in choosing the best drug options for the treatment and prophylaxis against SARS-CoV-2 (Fragkou et al., 2020). Therefore, different drug classes with prophylactic properties have been repositioned in order to guarantee protection against viral transmission (Zhou et al., 2020). This could lead to an interesting strategy targeting COVID-19 since it can be used as an additional barrier to viral spreading, as well as preventing disease evolution, especially for patients inside the risk groups. In this review, we present a systematic analysis of the main antiviral drug agents for many diseases, which can be proposed as new prophylaxis in clinical trials against SARS-CoV-2 infection and other therapeutic interventions.
Material and Methods
This systematic review was conducted in five stages: planning, bibliographic search, initial selection, final selection, summary of data and results. All of these steps were performed based on the bibliographic search protocol model developed by Kitchenham (2004). We used two indexing databases for the bibliographic search: PubMed (www.ncbi.nlm.nih.gov) and Scopus (www.scopus.com), in order to retrieve papers related to the proposed theme of this review, and considered publications until June 30, 2020. On the PubMed database searching, we considered 38 strings with the terms: “Covid-19,” “SARS-CoV-2,” “Coronavirus,” “2019 nCoV” and “Prophylaxis,” combined with 38 drug names. The Scopus database search produced eight strings, constructed using the following words: prophylaxis, prophylactic, pre-exposure, COVID-19, SARS-CoV-2, Chemoprophylaxis, repurposed, strategies, clinical, trials, anti-SARS-CoV-2, anti-covid-19, antiviral, therapy prevention in vitro, in cells, and human testing. The detailed steps on sorting publications are described in the Supplemental Material S1.
The publications retrieved were imported to MEDLINE (PubMed) and BIBTEX (Scopus) formats, and submitted to the StArt (State of the Art through Systematic Review) program v. 3.3 Beta 03 (Fabbri et al., 2016), developed by the Federal University of São Carlos (UFSCar), and available for download on http://lapes.dc.ufscar.br/tools/start_tool. Furthermore, we excluded duplicated records, and then all the preselected publications were entered into an Excel spreadsheet model for the next steps.
The initial selection of publications was based on the inclusion and exclusion criteria described in the following protocol. Initially, all the review articles, case studies, clinical guidelines, research strategies, short communications and unfinished studies were excluded. In a second phase, we included only publications of in vitro, in vivo research, and randomized clinical studies on the use of drugs for pre- and post-exposure prophylaxis for the treatment of COVID-19. Additionally, until the end of the review process, we included novel pre-clinical and clincal SARS-CoV-2 drug repurposing studies as a way of complementing the discussion about drug prophylaxis against COVID-19.
The corresponding metadata of used drugs for each study, test phases (I, II, and III), number of patients, cell lineages used in vitro tests, as well as in vivo test details were extracted from each accepted publication, and this information is presented in the Supplemental Material S2, as well as all 1,288 reference articles used in this work are reported in the Supplemental Material S3.
Additional information about drug efficacy, half-life, toxicity, interactions, and side effects were obtained from the public domain database Drugbank (https://www.drugbank.ca/).
In this review, we reported a significant number of articles with human clinical studies, in vivo animal experiments, in vitro cell studies, and in silico approaches, mainly for drug repurposing strategies. Furthermore, we evaluated literature material of 1,228 article records. The screening, selection, and exclusion processes of all the publications are detailed in Figure 1.
FIGURE 1. Detailed systematic review protocol and results for both PubMed and Scopus indexing bases with all the steps for inclusion and exclusion of potential prophylaxis articles.
After all the filtering steps included in our systematic protocol, we selected 60 articles to describe possible prophylaxis options for preclinical and clinical studies against SARS-CoV-2. The analysis of articles’ contents indicated that: 15 studies were done with clinical data; 22 studies used in vitro approaches against pathogenic virus strains responsible for airway and pulmonary infections, such as influenza and SARS-CoV-2; seven studies used animal models; and 18 studies performed in silico experiments against viral targets. Furthermore, we included 37 complementary articles discussing 23 drug mechanism of action as additional prophylaxis options.
Usually, the studies did not discuss drug half-life, as well as other pharmacokinetic parameters, such as Cmax, Tmax, and renal clearance. All the drug doses reported were those used for daily treatment for parasitic and viral infections. On the other hand, by using the information from the in vitro tests, it is possible to predict a range of inhibitory concentrations, which could assist in extrapolating the concentration parameters in clinical studies with humans. Nonetheless, extrapolation of plasma dose and concentration should be assessed and monitored in blood plasma, as prophylactic studies have shown that some broad-spectrum antiviral drugs should be administered in concentrations greater than those provided for clinical protocols. Thus, it is possible to create more effective therapeutic responses against COVID-19; however, increasing doses and adjustment may induce potential adverse and side effects, as well as toxic and drug interactions, which has not been reported in most of the clinical studies considered in this review. All the reported drugs for the accepted papers are included in Table 1.
TABLE 1. Screened drugs with potential for prophylaxis studies, and their correspondent number of citations and mechanism of action.
After completing the table, we generated a word map that reflects most important drugs and terms according to the frequency they appear in all the evaluated articles (Figure 2), as well as we showed a worldwide research distribution map (Figure 3) with all the antiviral drugs cited in the Table 1. Despite other terms, such as hydroxychloroquine and some immune, antibody, and anti-parasitic drugs also appeared in this word map, we only considered drugs with antiviral action. Furthermore, these other terms can be explored in other review and research studies.
FIGURE 2. Word map reflecting the most cited terms for all the evaluated articles used in the review processes.
FIGURE 3. Antiviral research distribution for the 22 selected drugs. (A) Most relevant countries for the selected drugs between 2003 and 2020. (B) Number of times cited per drug.
In this section, we make a brief description of each selected drug from Table 1, and their mechanisms of action in order to support a possible repurposing of these approved drugs as new candidates on clinical trials studies as antiviral options against SARS-CoV-2, mainly for prophylaxis but not only restricted to it.
Amantadine is an M2 (Matrix protein 2) viral membrane protein inhibitor, necessary for the efficient release of the viral genome during virus entry (Jing et al., 2008). This drug has been used in the prophylactic or symptomatic treatment of influenza A but also acts as an antiparkinsonian (Lamb et al., 2005). The main hypothesis indicates that amantadine could interfere with the gene expression of endosomal cysteine protease (cathepsin L or B) in SARS-CoV-2 (Smieszek et al., 2020).
Amodiaquine is an aminoquinoline antimalarial drug, which has been used in other antiviral studies as a protease inhibitor, such as DENV2 and West Nile virus NS2B-NS3 protease using BHK-21 and Vero cells (Boonyasuppayakorn et al., 2014; D’alessandro et al., 2020), and Ebola virus (EBOV) by blocking viral replication in Huh seven and Vero E6 cells with IC50 = 2.8–3.2 μM and 9.5–11 μM, respectively. Additionally, amodiaquine present a synergic effect against viral replication of the SARS-CoV-2 in Vero E6 cells when it is combined with nelfinavir, and it presents higher synergic index when copared with other antimalarial drugs such as chloroquine, hydroxychloroquine, quinacrine and mefloquine (Ianevski et al., 2020). One theoretical pharmachophore modeling study published in Chemrxiv reinforces a possible action of this aminoquinoline inhibitor against the SARS-CoV-2 virus, with a mechanism of blocking its main protease with a theoretical Ki of 0.073 μM(Acharya, 2020).
Amprenavir is a known inhibitor of the HIV protease enzyme, acting on the prevention of the gag-pol polyprotein cleavage and resulting in the formation of immature and non-infectious viral particles (Fung et al., 2000). Generally, HIV protease inhibitors are used in combination with at least two other anti-HIV drugs (Sadler et al., 2020). Recent in vitro studies demonstrated that amprenavir exhibited a considerable degree of inhibition against SARS-CoV-2 (Mugisha et al., 2020).
Apilimod is a known interleukin-13/23 production inhibitor by acting on the phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) enzyme (Cai et al., 2013), as well is a safety drug for humans with a profile at doses of up to 125 mg twice daily and a peak serum concentration of 0.265 ± 0.183 μM (Huang et al., 2020). This drug was tested in vitro studies against EBOV and Marburg virus (MARV) using Vero E6, Huh seven cells and macrophages (hMDMs), and it was found that this inhibitor was capable of blocks both viral infection in all cell types (Nelson et al., 2017), as well as blocked EBOV particle entry (Nelson et al., 2017; White et al., 2018) and trafficking in cell cytoplasm (Nelson et al., 2017), with low IC50 values (Nelson et al., 2017; White et al., 2018). Additionally, apilimod has blocked Zaire ebolavirus (ZEBOV) and SARS-CoV-2 in vitro replication by acting on the PIKfyve kinase and reducing the intracellular trafficking of viral particles, as well as viral entry using Vero E6 cells with IC50 of 10 nM (Kang et al., 2020). Furthermore, a large-scale drug repurposing study apilimod was responsible for blocking viral replication in human pneumocyte-like cells derived from induced pluripotent stem cells with IC50 raging from 0.088 to 0.012 μM, as well as exhibited antiviral activity in a primary human lung explant model (Huang et al., 2020). Other study with Vero E6 cell viral replication monitored by QRT-PCR assays, indicated that apilimod potentially decreased the amount of SARS-CoV-2 RNA in cell culture supernatants, with an IC50 of 12 mM and low cell toxicity (Shema Mugisha et al., 2020).
Baloxavir marboxyl is an influenza A and B antiviral, which inhibits the cap-dependent endonuclease necessary for viral replication, and this is the first representative of influenza-type PB2 inhibitors. Baloxavir is under investigation in the clinical trial NCT04327791 since March 2020, and it has been used in a combined therapy with oseltamivir 1 with hospitalized patients with influenza infections (Reina and Reina, 2019).
Darunavir is an HIV protease inhibitor used against HIV infection, especially indicated to patients with a previous antiretroviral therapy history (Lu et al., 2020). In silico studies indicated that this drug could function as a protease inhibitor, as well as also interact with the 3C-like proteinase. Additionally, darunavir can also bind to the proteins of the SARS-CoV-2 replication complex (Beck et al., 2020). In vitro data for this drug showed potential for SARS-CoV-2 inhibition (Yamamoto et al., 2020). On the other hand, darunavir has not showed antiviral activity against SARS-CoV-2 at clinically relevant concentrations yet (De Meyer et al., 2020), but four other clinical trials are between phases 3 and 4 in order to evaluate the efficacy, safety, and pharmacokinetic characteristics of this drug in combination with other antiviral and anti-parasitic compounds against COVID-19 (Ciesek, 2020; Elmekaty, 2020; Lu, 2020; Gilead Sciences, 2020).
Entecavir is a guanine analogue that directly inhibits the replication process of hepatitis B virus (HBV) by blocking its reverse transcriptase mechanism (Huynh et al., 2020; Shah et al., 2020). This drug was considered a possible inhibitor of both RNA-dependent RNA polymerase and the main protease enzyme, from SARS-CoV and SARS-CoV-2 viruses (Shah et al., 2020).
Faldaprevir is a known Hepatitis C virus (HCV) NS3-4A protease inhibitor (HCV) (Kanda et al., 2015; Kanda et al., 2015). Its effectiveness was also confirmed when combined with other drugs such as pegylated interferon alfa-2a and ribavirin for chronic HCV infection treatment (Sulkowski et al., 2013). In silico experiments indicated a possible mechanism of action of faldaprevir for inhibiting the new coronavirus enzymes (Böcher et al., 2020; Shah et al., 2020), suggesting that this drug could be tested in the next preclinical and clinical trials.
Faviparivir is a pyrazine analogue that acts as a prodrug and inhibits the RNA-dependent RNA polymerase (RdRp) and, consequently, blocks viral transcription and replication (de Farias et al., 2017; Furuta et al., 2017). This drug was approved for therapeutic use in Japan in 2014 for influenza viruses. Nevertheless, because RdRp catalytic domain is conserved among several types of RNA viruses, its mechanism of action supports a wide spectrum of viral targets such those against Ebola and, more recently, SARS-CoV-2. (Furuta et al., 2017; Madelain et al., 2017; Raoul, 2020).
Galidesivir is an adenosine analog acting through the mechanism of inhibiting the viral RNA polymerase (Zhang et al., 2020). In this case, the nucleoside analog (NA) is incorporated into the viral RNA to exhibit its antiviral activity. Moreover, another mechanism of action is the recognition of this nucleotide analog as a substrate by the viral RNA polymerase, which blocks the RNA replication. This drug was initially used for treating HCV infections, but it has been reported as also efficient against Ebola, Zika and Yellow Fever viruses (De Clercq, 2019; Elfiky, 2020). Other NAs, such as remdesivir, favipiravir, and ribavirin were reported to have efficacy against SARS-CoV-2 by blocking RdRp activity (Zhang et al., 2020).
GC376 is a dipeptidyl bisulfite adduct salt that has been early used in cell-based inhibition assays against the picornavirus-like supercluster (picornaviruses, caliciviruses, and coronaviruses), with its mechanism of action on the inhibition of viral 3C-like proteases (Kim et al., 2012). This drug was used in a clinical study with a fatal coronavirus infection, caused by the feline infectious peritonitis virus (FIPV), and the authors have reported that GC376 significantly reduced viral load and symptoms, decreased the viral RNA levels in the macrophages from the cats that received the antiviral treatment, as well as returned all the individuals to their normal conditions by clinical observations and laboratory testing (Chang et al., 2016). Furthermore, it was reported that GC376 was capable to block the 3C-Like protease from the porcine epidemic diarrhea virus (PEDV) in cell-based assays using Vero cells, and they included a protein-inhibitor complex crystallization. In this case, the authors verified that in cell-based assays the IC50 was 1.11± 1.13 μM (Pedersen et al., 2020). Recently, this inhibitor has been tested against the SARS-CoV-2 in studies using fluorescence resonance energy transfer (FRET)-based screening assays targeting the Mpro enzyme, with molecular docking confirmation, as well as checking antiviral effects in infected Vero E6 cell cultures with an EC50 of 0.91± 0.03 μM (Hung et al., 2020). Other studies have reported GC376 as potent SARS-CoV-2 3C-like protease inhibitor in comparison to other drugs, such as Boceprevir, and describing their mechanism of interaction (Fu et al., 2020). In addition, other study compared the efficacy of the GC376 by generating its analogue the GC373 using FRET and cell-based studied, and including protein crystallization. The authors reported both molecules acted as potent inhibitors against SARS-CoV-2 Mpro, and presenting EC50 of 1.5 μM for GC373 and for 0.92 μM GC376 (Vuong et al., 2020).
GS-441524 is a remdesivir metabolite with activity against SARS-CoV-2 Mpro in molecular docking studies. In addition, it exhibited potent antiviral activity against several RNA viruses, including SARS infections (Cho et al., 2012). Besides, this drug could provide synergistic effects in combination with other RdRp antagonist drugs (Huynh et al., 2020).
Lopinavir is an antiretroviral protease inhibitor used in combination with other drugs for the HIV-7 treatment (Kim et al., 2020), such as ritonavir (Wada et al., 2020), which is a peptidomimetic inhibitor designed for inhibiting HIV-1 protease and is currently under investigation for the treatment of COVID-19 (De Clercq, 2009). Clinical studies indicated a potential benefit for patients infected with SARS-CoV-2 treated with lopinavir in the early stage of the disease (Li et al., 2020; Lim et al., 2020; Wu et al., 2020). Moreover, some authors suggested a protective effect of lopinavir on post-exposure prophylaxis for Middle East Respiratory Syndrome (MERS) (Li et al., 2020), as well as in combination with other antivirals for benefiting the treatment of SARS and MERS, including the reduction of acute respiratory distress syndrome (ARDS) incidences and mortality during early treatment (Chan et al., 2003).
Nelfinavir is an antiretroviral protease inhibitor with in vitro activity against the SARS-CoV 3CL protease, and in silico/in vitro activity against SARS-CoV replication (Yuen et al., 2005). In silico experiments indicated nelfinavir as a SARS-CoV-2 Mpro inhibitor, which could act in combination with cepharanthine on the control of disease progression and transmission risk (Chow et al., 2004; Yamamoto et al., 2004; Yuen et al., 2005). In vitro findings showed that cepharanthine reduced coronavirus cell entry (Yamamoto et al., 2019; Ohashi et al., 2020). Additionally, clinical data suggest that nelfinavir exhibits good pharmacokinetics characteristics in humans, and, thus, could be a potential drug candidate prophylaxis and treatment for COVID-19 patients (Bimonte et al., 2020; Yamamoto et al., 2020).
Oseltamivir is an influenza A and B approved drug with action inhibiting the viral neuraminidase, which decreases the release of viral particles from host cells and reduces viral spread in the respiratory tract (Rosa and Santos, 2020; Shah et al., 2020). This drug was used in the initial months of the COVID-19 outbreak, whether combined or not with antibiotics and corticosteroids, as well as with multiple combinations with chloroquine and favipiravir clinical trials. It is important to observe that clinical trials with oseltamivir at concentrations lower than 100 μM showed no apparent in vitro antiviral effect against the SARS-CoV-2 (Choy et al., 2020). In a clinical trial article, the authors indicated that this drug is not effective inhibiting SARS-CoV-2 even at its highest concentration; however, they do not show details of the trial, which is important to correctly determine the stage of infection at which the drug was administered and its effectiveness against COVID-19 (Rosa and Santos, 2020).
PF-00835231 is a ketone-based designed for inhibiting the SARS-CoV-1 virus (Yen et al., 2004). Recently, two studies revealed this drug as a potent inhibitor which were tested by FRET assay and for antiviral activity in Vero E6 cells with an IC50 0.00027 ± 0.0001 μM for 3C-like protease (Hoffman et al., 2020), as well as demonstrated to be statistically more potent than remdesivir in assays with infected SARS-CoV-2 A549+ACE2 cells with an EC50 of 0.221 μM at 24 h, and 0.158 μM at 48 h without detectable cytotoxicity (de Vries et al., 2020).
Remdesivir is a nucleoside analog inhibitor of RNA polymerases with a large viral spectrum (Gordon et al., 2020), originally developed for the treatment against Ebola (Cheng et al., 2020), exhibiting antiviral effects against filoviruses, paramixoviruses, pneumoviruses, and coronaviruses (Wang et al., 2020). This drug has been tested both in vitro and in vivo experiments (mice and Rhesus monkeys) against SARS-CoV2 (Flanigan et al., 2020; Grein et al., 2020). Furthermore, clinical trials have been performed with SARS-CoV-2 infected adults and children in different dose ranges, and it has been demonstrating low toxicity (Hennon et al., 2020; Maharaj et al., 2020). Additionally, double-blind, randomized, multicenter clinical studies observed a significant improvement in the reduction of viral load during the infection but without a considerable reduction in the mortality rate compared to patients who received placebo in the same period (Wang et al., 2020). Moreover, in vitro cell culture Vero-E6 tests showed antiviral activity of this drug in the post-entry stage of the cells, with an EC50 of 1.76 μM in EC50 (Wang et al., 2020).
Ribavirin is a guanosine analogue antiviral with activity against DNA and RNA viral polymerases that has been showing promising results against SARS-CoV-2 (Alhazzani et al., 2020; Khalili et al., 2020; Yousefi et al., 2020; Zhang et al., 2020). Although this compound is established among the first five antiviral drugs tested in vitro against SARS-CoV-2 due to its promising results against previous SARS and MERS infections (Morgenstern et al., 2005; Wohlford-Lenane et al., 2009; Khalili et al., 2020), some authors indicated a need of dose reduction on the new coronaviruses treatment (McCray et al., 2020). The prophylactic use of this drug includes the association with lopinavir and ritonavir, or interferon-α (INF-α), instead of monotherapy. Studies about ribavirin in the SARS-CoV-2 treatment still lack information about mechanisms of action, dose response, and different clinical aspects (Khalili et al., 2020; Zhang et al., 2020).
Tenofovir is a real nucleotide analog that has a phosphate group attached to a nitrogenous base (Härter et al., 2020). Once activated, tenofovir acts via different mechanisms, doing a potent reverse transcriptase inhibition and blocking the chain termination in the viral replication. This is an FDA approved drug for HIV and hepatitis C treatment, and it is currently used against the human herpes simplex virus, inhibiting the viral DNA polymerase (McConville et al., 2014). With the ongoing COVID-19 pandemic, this drug has been used in clinical studies with patient concomitant infected with HIV and SARS-CoV-2 (Härter et al., 2020).
Umifenovir (arbidol) is an indole-based derivative, which inhibits the influenza virus binding fusion proteins mechanisms (Hemagglutinin) (Blaising et al., 2014). It is a broad-spectrum oral antiviral used for the treatment and prophylaxis of influenza A and B and other respiratory infections (Blaising et al., 2014). As an oral antiviral, it has been used for the treatment and prophylaxis of influenza and other viral respiratory infections, licensed for use in Russia in 1993 and in China since 2006 (Liu et al., 2009; Mani Mishra et al., 2020). This drug has proven effectiveness in vitro, in vivo, and clinical studies for different viruses, including influenza A and B, Zika, as well as agents of acute respiratory tract infection: adenovirus, respiratory syncytial virus, coronavirus or SARS virus, rhinovirus, parainfluenza virus (Brooks et al., 2012; Tannock et al., 2016; Kadam & Wilson, 2017; Fink et al., 2018; Haviernik et al., 2018; Maleev et al., 2019). Some authors reported that this drug effectively inhibited SARS-CoV-2 when compared to other anti-influenza drugs of therapeutic use (Wang et al., 2020), and it was effective (EC50) in a range of inhibitory concentration against influenza and within a range of maximum plasma concentration estimated to be effective for SARS-CoV-2 (Sun et al., 2013). Currently, umifenovir is under clinical investigation as a potential agent for the treatment and prophylaxis of SARS-CoV-2 infections (Mani Mishra et al., 2020) and the early treatment with this drug can decrease the incidences of pneumonia in a high-risk hospitalized population (Beigel et al., 2019). In addition, it can be suggested that arbidol is associated with a decrease in infection among exposed individuals by COVID-19 (Zhang et al., 2020). In silico studies for this drug displayed activity with several SARS-CoV-2 targets, such as Mpro and Spike proteins (Vankadari, 2020; Zhao et al., 2020).
Several of the accepted papers in this review reported drugs with promising results, mainly with in silico and in vitro studies, which can be considered for further in vivo and clinical trials experiments. Acyclovir is a nucleoside analog that inhibits the action of viral DNA polymerase and DNA replication of different herpesviruses (O’Brien and Campoli-Richards, 1989); however, it did not show any effect against 2019-nCoV (Li et al., 2020). Indinavir is an antiretroviral protease inhibitor used against type 1 HIV infection. In silico studies reported that this drug could be used as a probable inhibitor of the SARS-CoV-2 Mpro, according to molecular docking experiments with the crystallized structures 5R7Z, 5R80, 5R81 and 5R82 (Shah et al., 2020). Pleconaril is a drug used for prevention of asthma, as well as common cold symptoms in asthmatic individuals exposed to respiratory infections. This drug acts against Picornaviridae viruses, and in silico molecular docking experiments indicated that pleconaril could be a SARS-CoV-2 spike protein blocker and may be selected for further preclinical and clinical experiments against this virus (Böcher et al., 2020). Sofosbuvir is a nucleoside analog used against HCV infections that acts inhibiting the viral RNA-dependent polymerase, and in silico studies demonstrated that this compound could complex with the SARS-CoV2 RNA polymerase (Elfiky, 2020), as well as other viral enzymes (Shah et al., 2020). Tipranavir is a non-peptide inhibitor of the HIV protease indicated for combined antiretroviral treatment. This drug has been repurposed in silico studies against 3CL SARS-CoV-2 proteases (Böcher et al., 2020). Zanamivir is a direct-acting antiviral drug that acts as a neuraminidase inhibitor against influenza A and B (Elfiky, 2020), and in silico studies demonstrated interaction with viral transcription proteases against SARS-CoV2 (Shah et al., 2020). Additional studies have been reporting the broad-spectrum anti-parasitic drug ivermectin as a SARS-CoV-2 replication inhibitor (Caly et al., 2020), since other studies have reported many antiviral actions against HIV (Wagstaff et al., 2012; Caly et al., 2020; Heidary and Gharebaghi, 2020), DENV (Xu et al., 2018; Caly et al., 2020; Heidary and Gharebaghi, 2020), ZIKA (Caly et al., 2020; Heidary and Gharebaghi, 2020), and Influenza A (Götz et al., 2016; Heidary and Gharebaghi, 2020). This drug is a macrocyclic lactone with its main antiviral mechanism of action in the nuclear transport role of the host importin α (IMPα) protein (Jans and Wagstaff, 2020; Schwemmle et al., 2020). Furthermore, one study has showed that this molecule presented antiviral effects against the SARS-CoV-2 in vitro assays with Vero/hSLAM cells with 5000-fold reduction in viral RNA after 48 h with IC50 varying from 2.2 to 2.5 μM (Caly et al., 2020; Sharun et al., 2020). Teicoplanin is a glycopeptide antibiotic with its main activity to treat bacterial infection (Reynolds, 1989; Zhou et al., 2016). In vitro experiments demonstrated that this drug inhibited cell entry of the EBOV into primary human umbilical vein endothelial cells, A549 cells, HeLa cells, and THP-1 cells with an IC50 of 0.34 μM (Zhou et al., 2016), as well as its derivatives demonstrated antiviral activity against influenza strains, vaccinia, herpes, and human coronavirus (Bereczki et al., 2020). Recently, it was published that teicoplanin potently blocks the HIV-luc/2019-nCoV-S pseudoviruses entry into human A549 cells with a IC50 of 1.66 μM, suggesting this could be caused by the cathepsin L inhibition. Additionally, it was demonstrated that this drug repressed viral entrance into HEK293T and Huh7 cells (Zhang et al., 2020).
A recent study which performed a high-throughput screening using The ReFRAME library for drug repurposing against the SARS-CoV-2, investigated 11,987 FDA approved compounds in infected Vero E6 cell assays, and included a gene set enrichment analysis, which returned that they could be affecting viral replication and dynamics by acting in different targets, such as modulators of benzodiazepine receptors, aldose reductase, potassium channels, cholesterol homeostasis, serine proteases and retinoic acid receptor agonists. Furthermore, the authors realized an orthogonal validation of 300 active compounds with concentrations between 2.5 and 1 μM, and found 100 molecules that were capable to reduce viral replication, as well as several validated by the gene set enrichment analysis target classes. Compound efficacies were additionally checked with Huh-7 and HEK293T cells transduced with angiotensin-converting enzyme 2 (ACE2), and Thirteen compounds exhibited nanomolar EC50 values, including a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist DS-6930, the HIV-1 reverse transcriptase inhibitor R 82913, and the anti-mycobacterial clofazimine. Additionally, it was found that five of most potent inhibitors presented activity in the cell viral entry step but, on the other hand, it is suggestive that the protease inhibitors VBY-825, ONO 5334, Z LVG CHN2 and MDL 28170 are acting in host’s proteases once they have not acted on both SARS-CoV-2 3C-like and papain-like proteases. The compound Z LVG CHN2 is probably acting as an endosomal protease inhibitor whereas ONO 5334 is a cathepsin K inhibitor, and VBY-825 a cathepsin protease inhibitor. Another assay with human induced pluripotent stem cell (iPSC)-derived pneumocyte-like cells indicated that the molecules ONO 5334, MDL 28170 and apilimod drastically reduced the number of infected cells. Furthermore, an ex vivo lung culture system assay showed apilimod as a potent antagonist to viral replication in comparison to the positive control remdesivir (Huang et al., 2020; Wec et al., 2020).
A second recent study with a large-scale molecule library, with approximately 1000 FDA approved drugs and 2,100 drug-like molecules with validated pharmacological activity purchased from Selleckchem, performed an antiviral screening using Lung epithelial Calu-3 cells, Vero E6 and Huh7.5 cells. Initially, the authors found that remdesivir and hydroxychloroquine were active in infected Vero E6, with IC50 of 0.46 and 1.32 μM, respectively, as well as other six drugs including the natural compound nanchangmycin, with IC50 of 0.01 μM. Additionally, Huh7.5 cell assays demonstrated that 33 drugs were active with IC50 below 0.5 μM, including remdesivir, hydroxychloroquine and nanchangmycin. On the other hand, since remdesivir was active in infected Calu-3 cells, hydroxychloroquine and its derivates presented none activity. This suggests that there is a different mechanism of endosomal acidification in this cell types which turns the mechanism of action of the hydroxychloroquine and its derivatives, as well as the drug Z-FA-FMK ineffective in these cells but active in Vero E6 and Huh7.5. Thus, the authors suggested the role of the he plasma membrane-associated serine protease (TMPRSS2), allowing the SARS-CoV-2 entry in Calu-3 cells, and proposed a specific inhibition action of the drug camostat with IC50 of 0.35 μM since it has not presented activity in Vero E6 and Huh7.5 cells (Walker et al., 2020). This mechanism was also demonstrated in another study using human bronchial epithelial cells (HBEC), primary type II alveolar epithelial cells (AECII), and Calu-3 cells for Influenza A and B Virus (Limburg et al., 2019). On the other hand, recent clinical studies with hydroxychloroquine indicated a lack of efficacy in acute infected hospitalized patients with COVID-19, but with small cardiac effects and cardiac deaths (Giovanna and Carlo, 2020; Pan et al., 2020), which could indicate that this drug have its main action as a prophylactic agent, as well as in non-severe cases. Additionally, similar results were achieved for remdesivir, lopinavir (Pan et al., 2020), as well as for the combination between lopinavir and ritonavir (Horby et al., 2020). Thus, this is suggestive that these drugs could be used as prophylactic mechanisms, as well as in the early stages of COVID-19 infection in non-hospitalized patients. Therefore, further prophylactic studies are required for hydroxychloroquine, remdesivir and lopinavir, before they can be largely used by the physicians. Other nine drug candidates presented selective antiviral index greater than 2 against SARS-CoV-2 Calu-3 cells: Salinomycin, Y-320, AZD8055, bemcentinib, dacomitinib, WYE-125132, ebastine, Dp44mT, and cyclosporine (Limburg et al., 2019).
The new coronavirus pandemic caused by the SARS-CoV-2 has provoked a global health and economic crisis in most countries, which has mobilized a great number of scientific research groups in many fields of study, especially with drug therapy and vaccination, in order to find prophylaxis and therapeutic alternatives against the COVID-19. Although many research results have revealed palliative drug treatment against this infection focused in human targets, many other researches have been publishing drug repurposing experiments, using previous experimental data, with main targeting other viruses’ treatments, with in silico and in vitro experiments. On the other hand, clinical experiments with previously approved drugs against the new coronavirus lack in number of drug options, number of patients in different health conditions and control groups, as well as the time of evaluation, which is understandable, since only less than seven months have passed after the start of the SARS-CoV-2 outbreak. Furthermore, many vaccination options are still in different clinical test phases in many countries, without any guarantee to solve this global problem. Therefore, the use of clinical protocol-based scientific evidence data for SARS-CoV-2 prophylaxis, as well as for the daily routine in hospitals for its treatment, is crucial for controlling the disease spread, prognostic and patient recovery, and can indeed help save many lives.
In this review, we proposed a list of 22 approved drugs and compounds, with relevant clinical data, and in vivo, in vitro and in silico evidences, which can guide prophylaxis studies with large individual groups. Additionally, we included more 22 compounds between FDA approved drugs and drug-like like molecules, which were tested in large-scale screenings, as well as those repurposed approved drugs with new mechanism of actions. Furthermore, this review contributes to avoiding the concomitant use of drugs associated with polypharmacy (many times without scientific evidences), which can lead to serious health side and adverse effects, sometimes with toxic and degenerative drug interactions for humans. The integration between clinical trials data, in silico, in vitro, and in vivo screenings can assist in the rational use of new antiviral drugs not only for the COVID-19 prophylaxis, but also for its treatment, even in more advanced proliferation stages.
Data Availability Statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.
BA participated in the manuscript conceptualization, experimental design and writing, and supervision; FR writing and data analysis; NS experimental design, data analysis; AF, WS, and SS writing and data analysis; DB, AG-N, AB, and VA overall manuscript review and English review.
This work was supported by Grant from the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) Grant #88887.506611/202-00. Alexander Birbrair is supported by a Grant from Instituto Serrapilheira/Serra-1708-15285, a Grant from Pró-reitoria de Pesquisa/Universidade Federal de Minas Gerais (PRPq/UFMG) (Edital 05/2016), a Grant from CNPQ (Universal, Process No. 405977/2018-2), a Grant from National Institute of Science and Technology in Theranostics and Nanobiotechnology (CNPq/CAPES/FAPEMIG, Process No. 465669/2014-0), a Grant from FAPEMIG (Rede Mineira de Engenharia de Tecidos e Terapia Celular (REMETTEC, RED-00570-16)), a Grant from FAPEMIG (Rede De Pesquisa Em Doenças Infecciosas Humanas E Animais Do Estado De Minas Gerais (RED-00313-16)), and a productivity fellowship from the National Council for Scientific and Technological Development (CNPq).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors would like to thank to CNPq, CAPES, FAPESB, and FAPEMIG agencies, as well as The State University of Southwest of Bahia for supporting this work.
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2020.590598/full#supplementary-material.
Acharya, B. N. (2020). Amodiaquine as COVID-19 Mpro inhibitor: a theoretical study. Available at: https://chemrxiv.org/articles/preprint/Amodiaquine_as_COVID-19_Mpro_Inhibitor_A_Theoretical_Study/12555137
Alhazzani, W., Møller, M. H., Arabi, Y. M., Loeb, M., Gong, M. N., Fan, E., et al. (2020). Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intens. Care Med. 48, 423–469. doi:10.1097/ccm.0000000000004363
Beck, B. R., Shin, B., Choi, Y., Park, S., and Kang, K. (2020). Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput. Struct. Biotechnol. J. 18, 784–790. doi:10.1101/2020.01.31.929547
Beigel, J. H., Nam, H. H., Adams, P. L., Krafft, A., Ince, W. L., El-Kamary, S. S., et al. (2019). Advances in respiratory virus therapeutics – a meeting report from the 6th isirv Antiviral Group conference. Antivir. Res. 167, 43–67. doi:10.1016/j.antiviral.2019.04.006
Bereczki, I., Csávás, M., Szűcs, Z., Rőth, E., Batta, G., Ostorházi, E., et al. (2020). Synthesis of antiviral perfluoroalkyl derivatives of teicoplanin and vancomycin. ChemMedChem 15, 1661–1667. doi:10.1002/cmdc.202000260
Bimonte, S., Crispo, A., Amore, A., Celentano, E., Cuomo, A., and Cascella, M. (2020). Potential antiviral drugs for SARS-Cov-2 treatment: preclinical findings and ongoing clinical research. In Vivo 34, 1597–1602. doi:10.21873/invivo.11949
Boonyasuppayakorn, S., Reichert, E. D., Manzano, M., Nagarajan, K., and Padmanabhan, R. (2014). Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity. Antivir. Res. 106, 125. doi:10.1016/j.antiviral.2014.03.014
Brooks, M. J., Burtseva, E. I., Ellery, P. J., Marsh, G. A., Lew, A. M., Slepushkin, A. N., et al. (2012). Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions. J. Med. Virol. 84, 170–181. doi:10.1002/jmv.22234
Cai, X., Xu, Y., Cheung, A. K., Tomlinson, R. C., Alcázar-Román, A., Murphy, L., et al. (2013). PIKfyve, a class III PI Kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in toll-like receptor signaling. Chem. Biol. 20, 912. doi:10.1016/j.chembiol.2013.05.010
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., and Wagstaff, K. M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir. Res. 178, 104787. doi:10.1016/j.antiviral.2020.104787
Chan, K. S., Lai, S. T., Chu, C. M., Tsui, E., Tam, C. Y., Wong, M. M., et al. (2003). Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med. J., 9, 399. doi:10.22541/au.159040088.84670621
Chang, Y., Liu, H., Galasiti Kankanamalage, A. C., Weerasekara, S., Hua, D. H., Groutas, W. C., et al. (2016). Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor. PLoS Pathog. 12, e1005531. doi:10.1371/journal.ppat.1005531
Cheng, M. P., Lee, T. C., Tan, D. H. S., and Murthy, S. (2020). Generating randomized trial evidence to optimize treatment in the COVID-19 pandemic. Can. Med. Assoc. J. 192, E405–E407. doi:10.1503/cmaj.200438
Cho, A., Saunders, O. L., Butler, T., Zhang, L., Xu, J., Vela, J. E., et al. (2012). Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorg. Med. Chem. Lett. 22, 2705. doi:10.1016/j.bmcl.2012.02.105
Chow, C-Y., Jan, J-T., Ma, S-H., Kuo, C-J., Juan, H-F., Cheng, Y-S. E., et al. (2004). Small molecules targeting severe acute respiratory syndrome human coronavirus. Available at: www.pnas.orgcgidoi10.1073pnas.0403596101.
Choy, K. T., Wong, A. Y., Kaewpreedee, P., Sia, S. F., Chen, D., Hui, K. P. Y., et al. (2020). Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 178, 104786. doi:10.1016/j.antiviral.2020.104786
Ciesek, Y. (2020). Ivermectin vs combined hydroxychloroquine and antiretroviral drugs (ART) among Asymptomatic COVID-19 infection, (IDRA-COVID19). Available at: https://clinicaltrials.gov/ct2/show/NCT04435587.
De Meyer, S., Bojkova, D., Cinatl, J., Van Damme, E., Buyck, C., Van Loock, M., et al. (2020). Lack of antiviral activity of darunavir against SARS-CoV-2. Int. J. Infect. Dis. 97, 7–10. doi:10.1016/j.ijid.2020.05.085
de Vries, M., Mohamed, A. S., Prescott, R. A., Valero-Jimenez, A. M., Desvignes, L., O’Connor, R., et al. (2020). Comparative study of a 3CLpro inhibitor and remdesivir against both major SARS-CoV-2 clades in human airway models. bioRxiv Available at: http://biorxiv.org/content/early/2020/08/28/2020.08.28.272880.abstract.
D’alessandro, S., Scaccabarozzi, D., Signorini, L., Perego, F., Ilboudo, D. P., Ferrante, P., et al. (2020). The use of antimalarial drugs against viral infection. Microorganisms 8, 85. doi:10.3390/microorganisms8010085
Elmekaty, E. (2020). Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar (DOLCI)—NCT04425382. Available at: https://clinicaltrials.gov/ct2/show/NCT04425382.
Fabbri, S., Silva, C., Hernandes, E., Octaviano, N. F., Di Thommazo, A., and Belgamo, A. (2018). Improvements in the StArt tool to better support the systematic review process. ACM Int. Conf Proc. Ser.
Fink, S. L., Vojtech, L., Wagoner, J., Slivinski, N. S. J., Jackson, K. J., Wang, R., et al. (2018). The antiviral drug arbidol inhibits Zika virus. Sci. Rep. 20, 183. doi:10.1016/0166-3542(93)90641-u
Flanigan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J., et al. (2020). Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 11, 22. doi:10.1038/s41467-019-13940-6
Fragkou, P. C., Belhadi, D., Peiffer-Smadja, N., Moschopoulos, C. D., Lescure, F. X., Janocha, H., et al. (2020). Review of trials currently testing treatment and prevention of COVID-19. Clin. Microbiol. Infect. 26, 988–998. doi:10.1016/j.cmi.2020.05.019
Fu, L., Ye, F., Feng, Y., Yu, F., Wang, Q., Wu, Y., et al. (2020). Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat. Commun. 11, 33–69. doi:10.1038/s41467-020-18233-x
Gilead Sciences (2020). Virologically suppressed pediatric participa. Study evaluating pharmacokinetics (PK), safety, and efficacy of cobicistat-boosted Atazanavir (ATV/co) or cobicistat-boosted darunavir (DRV/co) and Emtricitabine/tenofovir Alafenamide (F/TAF) in HIV-1 infected. Open Forum Infect. Dis. 2, 93. doi:10.1093/ofid/ofv131.79
Gordon, C. J., Tchesnokov, E. P., Feng, J. Y., Porter, D. P., and Götte, M. (2020). The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J. Biol. Chem. 295, 4773–4779. doi:10.1074/jbc.AC120.013056
Götz, V., Magar, L., Dornfeld, D., Giese, S., Pohlmann, A., Höper, D., et al. (2016). Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. Sci. Rep.6, 23138. doi:10.1038/srep23138
Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., et al. (2020). Compassionate use of remdesivir for patients with severe Covid-19. N. Engl. J. Med. 382, 2327–2336. doi:10.1056/NEJMoa2007016
Härter, G., Spinner, C. D., Roider, J., Bickel, M., Krznaric, I., Grunwald, S., et al. (2020). COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. Berlin, Springer.
Haviernik, J., Štefánik, M., Fojtíková, M., Kali, S., Tordo, N., Rudolf, I., et al. (2018). Arbidol (Umifenovir): A broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses. Viruses 10, 184. doi:10.3390/v10040184
Hennon, T. R., Penque, M. D., Abdul-Aziz, R., Alibrahim, O. S., McGreevy, M. B., Prout, A. J., et al. (2020). COVID-19 associated multisystem inflammatory syndrome in children (MIS-C) guidelines; a western New York approach. Prog. Pediatr. Cardiol. 57, 101232. doi:10.1016/j.ppedcard.2020.101232
Hoffman, R. L., Kania, R. S., Brothers, M. A., Davies, J. F., Ferre, R. A., Gajiwala, K. S., et al. (2020). The discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J. Med. Chem. 63, 12725–12747. doi:10.1021/acs.jmedchem.0c01063
Horby, P. W., Mafham, M., Bell, J. L., Linsell, L., Staplin, N., Emberson, J., et al. (2020). Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 96, 1345. doi:10.1016/s0140-6736(20)32013-4
Huang, L., Yuan, S., Yin, X., Martin-Sancho, L., Matsunaga, N., Pache, L., et al. (2020). Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 19, 33–57. doi:10.1136/bmj.m2650
Hung, H. C., Ke, Y. Y., Huang, S. Y., Huang, P. N., Kung, Y. A., Chang, T. Y., et al. (2020). Discovery of M protease inhibitors encoded by SARS-CoV-2. Antimicrob. Agents Chemother. 63, 12725–12747. doi:10.5867/medwave.2020.06.7966
Huynh, T., Wang, H., and Luan, B. (2020). Silico exploration of the molecular mechanism of clinically oriented drugs for possibly inhibiting SARS-CoV-2’s main protease. J. Phys. Chem. Lett. 63, 12725–12747. doi:10.1021/acs.jpclett.0c00994.s001
Ianevski, A., Yao, R., Fenstad, M. H., Biza, S., Zusinaite, E., Reisberg, T., et al. (2020). Potential antiviral options against SARS-CoV-2 infection. Viruses 63, 12725–12747. doi:10.22541/au.159294191.15961895
Jing, X., Ma, C., Ohigashi, Y., Oliveira, F. A., Jardetzky, T. S., Pinto, L. H., et al. (2008). Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Proc. Natl. Acad. Sci. U.S.A. 105, 10967–10972. doi:10.1073/pnas.0804958105
Kang, S., Peng, W., Zhu, Y., Lu, S., Zhou, M., Lin, W., et al. (2020). Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment. Int. J. Antimicrob. Agents 55, 19. doi:10.1016/j.ijantimicag.2020.105950
Kang, Y. L., Chou, Y. Y., Rothlauf, P. W., Liu, Z., Soh, T. K., Cureton, D., et al. (2020). Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. Proc. Natl. Acad. Sci. U.S.A. 93, 127. doi:10.1101/2020.04.21.053058
Khalili, J. S., Zhu, H., Mak, N. S. A., Yan, Y., and Zhu, Y. (2020). Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID-19. J. Med. Virol. 92, 740–746. doi:10.1002/jmv.25798
Kim, Y., Lovell, S., Tiew, K. C., Mandadapu, S. R., Alliston, K. R., Battaile, K. P., et al. (2012). Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J. Virol. 86, 11754. doi:10.1128/JVI.01348-12
Krakower, D. S., Oldenburg, C. E., Mitty, J. A., Wilson, I. B., Kurth, A. E., Maloney, K. M., et al. (2015). Knowledge, beliefs and practices regarding antiretroviral medications for HIV prevention: results from a survey of healthcare providers in New England. PLoS One, 10, e0132398. doi:10.1371/journal.pone.0132398
Lamb, T. A., Clarke, R. J., and Johnson, J. W. (2005). Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J. Neurosci. 25, 3312–3322. doi:10.1523/JNEUROSCI.4262-04.2005
Li, S. J., Yu, K. M., Kim, Y. Il., Kim, S. M., Kim, E. H., Kim, S. G., et al. (2020). Antiviral efficacies of FDA-approved drugs against SARS-COV-2 infection in ferrets. mBio 11, 1–10. doi:10.1101/2020.05.12.090035
Lim, J., Jeon, S., Shin, H. Y., Kim, M. J., Seong, Y. M., Lee, W. J., et al. (2020). Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J. Kor. Med. Sci. Kor. Acad. Med. Sci. 7, 35. doi:10.3346/jkms.2020.35.e88
Limburg, H., Harbig, A., Bestle, D., Stein, D. A., Moulton, H. M., Jaeger, J., et al. (2019). TMPRSS2 is the major activating protease of influenza A virus in primary human airway cells and influenza B virus in human type II pneumocytes. J. Virol. 5, 68–83. doi:10.1128/jvi.00649-19
Liu, M. Y., Wang, S., Yao, W. F., Wu, H. Z., Meng, S. N., and Wei, M. J. (2009). Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers. Clin. Therapeut. 31, 784–792. doi:10.1016/j.clinthera.2009.04.016
Lu, H. (2020). Efficacy and safety of darunavir and Cobicistat for treatment of COVID-19. (DC-COVID-19)—NCT04252274. Available at: https://clinicaltrials.gov/ct2/show/NCT04252274.
Madelain, V., Guedj, J., Mentré, F., Nguyen, T. H., Jacquot, F., Oestereich, L., et al. (2017). Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy studies of hemorrhagic fever viruses. Antimicrob. Agents Chemother., 61, 44. doi:10.1128/AAC.01305-16
Maharaj, A. R., Wu, H., Hornik, C. P., Balevic, S. J., Hornik, C. D., Smith, P. B., et al. (2020). Simulated assessment of pharmacokinetically guided dosing for investigational treatments of pediatric patients with coronavirus disease 2019. JAMA Pediatr. 27705, e202422. doi:10.1001/jamapediatrics.2020.2422
Maleev, N. Y., Bulgakova, V. A., Lvov, N. I., Poromov, A. A., Selkova, E. P., Grekova, A. I., et al. (2019). Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR). Ter Arkh. Consilium Medikum 91, 56–63. doi:10.37473/dac/10.7774/cevr.2020.9.2.183
Mayer, J. M., Orkin, C., Iser, D. M., Zamora, F. X., Nelson, M., Stephan, C., et al. (2015). Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 385, 1098. doi:10.1016/S0140-6736(14)62483-1
McConville, C., Boyd, P., and Major, I. (2014). Efficacy of tenofovir 1% vaginal gel in reducing the risk of HIV-1 and HSV-2 infection. Clin. Med. Insights Women's Health 7, 1. doi:10.4137/CMWH.S10353
Morgenstern, B., Michaelis, M., Baer, P. C., Doerr, H. W., and Cinatl, J. (2005). Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem. Biophys. Res. Commun. 326, 905–908. doi:10.1016/j.bbrc.2004.11.128
Mugisha, C. S., Vuong, H. R., Puray-Chavez, M., and Kutluay, S. B. (2020). A facile Q-RT-PCR assay for monitoring SARS-CoV-2 growth in cell culture. Available at: https://doi.org/10.1101/2020.06.26.174698.
Nelson, E. A., Dyall, J., Hoenen, T., Barnes, A. B., Zhou, H., Liang, J. Y., et al. (2017). The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection. PLoS Neglected Trop. Dis., 11, e0005540. doi:10.1371/journal.pntd.0005540
Ohashi, H., Watashi, K., Saso, W., Shionoya, K., Iwanami, S., Hirokawa, T., et al. (2020). Multidrug treatment with nelfinavir and cepharanthine against COVID-19. Available at: https://doi.org/10.1101/2020.04.14.039925.
O’Brien, J. J., and Campoli-Richards, D. M. (1989). Acyclovir: an updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 4, 33. doi:10.1158/1078-0432.ccr-03-0060
Pedersen, G., Wang, X., Tong, X., Shi, Y., Fu, Z. F., and Peng, G. (2020). Structural basis for inhibiting porcine epidemic diarrhea virus replication with the 3C-Like protease inhibitor GC376. Viruses.
Reina, J., and Reina, N. (2019). The Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) Baloxavir marboxil: a potent cap-dependent endonuclease inhibitor of influenza viruses Baloxavir marboxil: un potente inhibidor de la endonucleasa cap-dependiente de los virus gripales. Available at: https://creativecommons.org/licenses/by-nc/4.0/.
Rockstroh, T., Zhang, J., Yang, Y., Ma, H., Li, Z., Zhang, J., et al. (2020). The role of interleukin‐6 in monitoring severe case of coronavirus disease 2019. EMBO Mol Med. 19, 233–344. doi:10.15252/emmm.202012421
Sadler, B. M., Hanson, C. D., Chittick, G. E., Symonds, W. T., and Roskell, N. S. (2020). Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Available at: http://aac.asm.org/.
Schwemmle, S. N. Y., Atkinson, S. C., Wang, C., Lee, A., Bogoyevitch, M. A., Borg, N. A., et al. (2020). The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antivir. Res. 14, 73–79. doi:10.1055/a-1288-4078
Sharun, K., Dhama, K., Patel, S. K., Pathak, M., Tiwari, R., Singh, B. R., et al. (2020). Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann. Clin. Microbiol. Antimicrob. 252, 117652. doi:10.1007/s40278-020-84617-9
Shema Mugisha, C., Vuong, H. R., Puray-Chavez, M., Bailey, A. L., Fox, J. M., Chen, R. E., et al. (2020). A simplified quantitative real-time PCR assay for monitoring SARS-CoV-2 growth in cell culture. Oxford: mSphere.
Smieszek, S. P., Przychodzen, B. P., and Polymeropoulos, M. H. (2020). Amantadine disrupts lysosomal gene expression: a hypothesis for COVID19 treatment. Int. J. Antimicrob. Agents 252, 117652. doi:10.1007/978-1-4614-0560-3_1459
Sulkowski, M. S., Asselah, T., Lalezari, J., Ferenci, P., Fainboim, H., Leggett, B., et al. (2013). Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology, 57, 2143. doi:10.1002/hep.26276
Sun, Y., He, X., Qiu, F., Zhu, X., Zhao, M., Li-Ling, J., et al. (2013). Pharmacokinetics of single and multiple oral doses of arbidol in healthy Chinese volunteers. Int. J. Clin. Pharm. Ther., 51, 423. doi:10.5414/CP201843
Tannock, I. A., Burtseva, E. I., Yatsyshina, S. B., Fedyakina, I. T., Kirillova, E. S., Selkova, E. P., et al. (2016). Virus susceptibility and clinical effectiveness of anti-influenza drugs during the 2010-2011 influenza season in Russia. Int. J. Infect. Dis. 43, 77–84. doi:10.1016/j.ijid.2016.01.001
Vuong, W., Khan, M. B., Fischer, C., Arutyunova, E., Lamer, T., Shields, J., et al. (2020). Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat. Commun. 11, 24–28. doi:10.1016/s0165-5728(00)00266-6
Wada, T., Shimode, K., Hoshiyama, T., Takayama, Y., and Yamaoka, K. (2020). Three novel COVID-19 pneumonia cases successfully treated with lopinavir/ritonavir. Front Med. Frontiers Media S.A. 4, 33–39. doi:10.3109/08820139509060722
Wagstaff, K. M., Sivakumaran, H., Heaton, S. M., Harrich, D., and Jans, D. A. (2012). Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem. J., 443, 851. doi:10.1042/BJ20120150
Walker, M., Lee, J. S., Whig, K., Segrist, E., Li, M., Jurado, K., et al. (2020). Drug repurposing screens reveal FDA approved drugs active against SARS-CoV-2. SSRN Electron. J. 11, 24–28. doi:10.1016/j.phymed.2014.04.029
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., et al. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 47, 59–63. doi:10.3410/f.737311964.793572693
Wang, X., Cao, R., Zhang, H., Liu, J., Xu, M., Hu, H., et al. (2020). The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov 6, 4–8. doi:10.3410/f.737311964.793575075
Wang, Z., Chen, X., Lu, Y., Chen, F., and Zhang, W. (2020). Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 31 14. doi:10.5582/bst.2020.01030
Wec, A. Z., Wrapp, D., Herbert, A. S., Maurer, D., Haslwanter, D., Sakharkar, M., et al. (2020). Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein. bioRxiv 21, 096511. doi:10.1101/2020.05.15.096511
White, S., Leung, A., Bo, Y., Kozak, R. A., Anand, S. P., Warkentin, C., et al. (2018). Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry. Virology. 31 14. doi:10.3410/f.738912755.793579801
Wohlford-Lenane, C. L., Meyerholz, D. K., Perlman, S., Zhou, H., Tran, D., Selsted, M. E., et al. (2009). Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease. J. Virol. 83, 11385–11390. doi:10.1128/JVI.01363-09
Wu, J., Li, W., Shi, X., Chen, Z., Jiang, B., Liu, J., et al. (2020). Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J. Intern. Med.288, 128–138. doi:10.1111/joim.13063
Xu, T. L., Han, Y., Liu, W., Pang, X. Y., Zheng, B., Zhang, Y., et al. (2018). Antivirus effectiveness of ivermectin on dengue virus type 2 in Aedes albopictus. PLoS Neglected Trop. Dis. 4, 677–688. doi:10.1007/978-1-4615-1325-4_100
Yamamoto, D. E, Min, J. S., Jang, M. S., Lee, J. Y., Shin, Y. S., Park, C. M., et al. (2019). Natural bis-benzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus oc43 infection of mrc-5 human lung cells. Biomolecules 9, 696. doi:10.3390/biom9110696
Yamamoto, N., Matsuyama, S., Hoshino, T., and Yamamoto, N. (2020). Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro. Available at: https://doi.org/10.1101/2020.04.06.026476.
Yamamoto, N., Yang, R., Yoshinaka, Y., Amari, S., Nakano, T., Cinatl, J., et al. (2004). HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem. Biophys. Res. Commun. 318, 719–725. doi:10.1016/j.bbrc.2004.04.083
Yen, R. L., Kania, R., Steven, N., and James, S. (2004). Anticoronviral compounds and compositions, their pharmaceutical uses and materials for their synthesis. Available at: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2005113580.
Yousefi, B., Valizadeh, S., Ghaffari, H., Vahedi, A., Karbalaei, M., and Eslami, M. (2020). A global treatments for coronaviruses including COVID-19. J. Cell. Physiol. 283, 73–147. doi:10.1021/ol0630245.s001
Yuen, Y. C., Huang, V., Chao, T. C., Hsiao, C. D., Lin, A., Chang, M. F., et al. (2005). Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease. Biochem. Biophys. Res. Commun. 333, 194–199. doi:10.1016/j.bbrc.2005.05.095
Zhang, J., Ma, X., Yu, F., Liu, J., Zou, F., Pan, T., et al. (2020). Teicoplanin potently blocks the cell entry of 2019-nCoV. Available from: http://biorxiv.org/content/early/2020/02/13/2020.02.05.935387.abstract.
Zhang, J. nong., Wang, W., Peng, B., Peng, W., Zhang, Y. sheng., Wang, Y., et al. (2020). Potential of arbidol for post-exposure prophylaxis of COVID-19 transmission—a preliminary report of a retrospective cohort study. Curr. Med. Sci. 7, 180–251. doi:10.1002/minf.202000080
Zhang, W. F., Stephen, P., Thériault, J. F., Wang, R., and Lin, S. X. (2020). Novel coronavirus polymerase and nucleotidyl-transferase structures: potential to target new outbreaks. J. Phys. Chem. Lett. 11, 4430–4435. doi:10.1021/acs.jpclett.0c00571
Zhao, D., Orlov, A., Osolodkin, D. I., Ishmukhametov, A. A., Marcou, G., and Varnek, A. (2020). A chemographic audit of anti-coronavirus structure-activity information from public databases (ChEMBL). Mol Inform. 13, 44–59. doi:10.26434/chemrxiv.12104010
Zhou, N., Pan, T., Zhang, J., Li, Q., Zhang, X., Bai, C., et al. (2016). Glycopeptide antibiotics potently inhibit cathepsin l in the late endosome/lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J. Biol. Chem. 14, 91. doi:10.1038/s41421-020-0153-3
Keywords: SARS-CoV-2, prophylaxis, antiviral, drug repurposing, COVID-19
Citation: Andrade BS, Rangel FdS, Santos NO, Freitas AdS, Soares WRdA, Siqueira S, Barh D, Góes-Neto A, Birbrair A and Azevedo VAdC (2020) Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review. Front. Pharmacol. 11:590598. doi: 10.3389/fphar.2020.590598
Received: 02 September 2020; Accepted: 18 November 2020;
Published: 14 December 2020.
Edited by:Filippo Drago, University of Catania, Italy
Reviewed by:Kuldeep Dhama, Indian Veterinary Research Institute (IVRI), India
Arnab K. Chatterjee, Calibr at Scripps Research, United States
Copyright © 2020 Andrade, Rangel, Santos, Freitas, Soares, Siqueira, Barh, Góes-Neto, Birbrair and Azevedo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Bruno Silva Andrade, email@example.com